伊索显280与欧乃派克300脑血管造影随机双盲临床对比试验  

Randomized Double-blind Clinical Trial of the X-ray Contrast Media Isovist 280 VS Omnipaque 300 for Cerebral Angiography

作　　者：黄永火[1] 张克随[1] 曾勇明[1] 高必琼 唐文渊[1] 

机构地区：[1]重庆医科大学附属第一医院放射科

出　　处：《中国药房》1996年第2期79-80,共2页China Pharmacy

摘　　要：本文报告５８例伊索显２８０与欧乃派克３００脑血管造影对比随机双盲临床试验，其中３０例应用伊索显２８０，２８例应用欧乃派克３００实验。实验证明大多数调查者认为两种造影剂的质量好（伊索显占９２．６％，欧乃派克占９４．３％）。在检查期间，两组的副反应显示率相似（ｐ＞０．０５，无显著差异）。检查后，在大组中伊索显２８０总的副反应率低于欧乃派克３００（ｐ＜０．０５，有显著差异）检查后，在大组中伊索显２８０头痛的发生率明显低于欧乃派克３００（ｐ＜０．０５，有极显著差异）。伊索显２８０副反应的病例比欧乃派克副反应的病例少，程度轻，因此伊索显２８０对脑血管造影是一种有效、耐受性好和安全的造影剂。This paper reports a randomized double-blind clinical trial of two kinds of X-ray contrast media,Isovist 280 (30 cases) and Omnipaque 300 (28 cases), for cerebral angiography in 58 patients.Most investigators considered the contrast quality of both media satisfactory (92.6% for Isovist and 94.3% for Omnipaque). During contrast examination, there was no significant difference (p>0.05) in side effects induced by two kinds of contrast media. After examination, the total side effect rate of Isovist was lower than that of Omnipaque (p<0.05), moreover, Isovist induced less headache.We consider that Isovist 280 is an effective, well-tolerated and safe X-ray contrast medium for cerebal angiography.

关 键 词：脑血管造影 双盲临床试验 造影剂 伊索显 

分 类 号：R981.1[医药卫生—药品]